The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 401–500 of 1,006
Suramin inhibits cullin-RING E3 ubiquitin ligases
Wu, K., Chong, R. A., Yu, Q., Bai, J., Spratt, D. E., Ching, K., Lee, C., Miao, H., Tappin, I., Hurwitz, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601089113 · Cited by 62
Cavenagh, J. D., Oakervee, H. E., Caguioa, P. B., Davies, F. E., Gharibo, M. M., Rabin, N. K., Kurman, M. R., Novak, B. A., Shiraishi, N., Nakashima, D., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.302 · Cited by 58
Lazarian, G., Yin, S., ten Hacken, E., Sewastianik, T., Uduman, M., Font‐Tello, A., Gohil, S. H., Li, S., Kim, E., Joyal, H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.003 · Cited by 57
Self-citationTargeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 60
Chen, J., Zhu, W., Liu, J., Wang, G., Chen, X., Tan, Y., Xu, W., Qu, L.-W., Li, J., Yang, H.-J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00811-0 · Cited by 64
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury
Cheng, J., Jiang, J., He, B., Lin, W., Li, Y., Duan, J., Li, H., Huang, X., Cai, J., Xie, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm6543 · Cited by 57
Clinical Translation of Targeted Protein Degraders
Kong, N. R., & Jones, L. H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2985 · Cited by 59
Cereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 60
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 58
Nakayama, Y., Kosek, J., Capone, L., Hur, E. M., Schafer, P. H., & Ringheim, G. E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601725 · Cited by 54
Structural Biology of CRL Ubiquitin Ligases
Rusnac, D.-V., & Zheng, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_2 · Cited by 57
Decoding the messaging of the ubiquitin system using chemical and protein probes
Henneberg, L. T., & Schulman, B. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.009 · Cited by 56
Confounding Factors in Targeted Degradation of Short-Lived Proteins
Vetma, V., Perez, L. C., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00152 · Cited by 55
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
Burslem, G. M., Ottis, P., Jaime‐Figueroa, S., Morgan, A., Cromm, P. M., Toure, M., & Crews, C. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800271 · Cited by 52
Ullah, K., Zubia, E., Narayan, M., Yang, J., & Xu, G. (2018) · FEBS Journal · doi:10.1111/febs.14708 · Cited by 60
Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)
Krajcovicova, S., Jorda, R., Hendrychova, D., Krystof, V., & Soural, M. (2019) · Chemical Communications · doi:10.1039/c8cc08716d · Cited by 53
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation
Basu, A. A., Zhang, C., Riha, I. A., Magassa, A., Campos, M. A. L., Caldwell, A. G., Ko, F., & Zhang, X. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01655-9 · Cited by 55
Ushering in the next generation of precision trials for pediatric cancer
DuBois, S. G., Corson, L., Stegmaier, K., & Janeway, K. A. (2019) · Science · doi:10.1126/science.aaw4153 · Cited by 55
Mathien, S., Tesnière, C., & Meloche, S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000170 · Cited by 57
Silva, M. C., Nandi, G., Donovan, K. A., Cai, Q., Berry, B. C., Nowak, R. P., Fischer, E. S., Gray, N. S., Ferguson, F. M., & Haggarty, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.801179 · Cited by 54
Michaelides, I. N., & Collie, G. W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01882 · Cited by 54
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 56
Routes to molecular glue degrader discovery
Liu, Y., Bai, J., Li, D., & Cang, Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.006 · Cited by 57
Pak, C., Callander, N. S., Young, E. W. K., Titz, B., Kim, K., Saha, S., Chng, K., Asimakopoulos, F., Beebe, D. J., & Miyamoto, S. (2015) · Integrative Biology · doi:10.1039/c5ib00071h · Cited by 52
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 53
Jones, R. J., Iempridee, T., Wang, X., Lee, H. C., Mertz, J. E., Kenney, S. C., Lin, H. C., Baladandayuthapani, V., Dawson, W. O., Shah, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2242 · Cited by 54
Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 57
Ubiquitin-Dependent Regulation of Stem Cell Biology
Werner, A. A., Manford, A. G., & Rapé, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.002 · Cited by 56
Díaz, T., Rodríguez, V., Lozano, E., Mena, M.-P., Calderón, M., Rosiñol, L., Martínez, A., Tovar, N., Pérez‐Galán, P., Bladé, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164632 · Cited by 54
Cermakova, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 48
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 58
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51
Welsh, S. J., Barwick, B. G., Meermeier, E. W., Riggs, D. L., Shi, C.-X., Zhu, Y. X., Sharik, M. E., Du, M. T., Rocha, L. D. A., Garbitt, V. M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0062 · Cited by 53
Malek, E., Rana, P. S., Swamydas, M., Daunov, M., Miyagi, M., Murphy, E., Ignatz-Hoover, J. J., Metheny, L. L., Kim, S.-J., & Driscoll, J. J. (2024) · Nature Communications · doi:10.1038/s41467-024-51442-2 · Cited by 54
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 53
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell
Sayed, N., Ameen, M., & Wu, J. C. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz024 · Cited by 51
Cereblon enhancer methylation and IMiD resistance in multiple myeloma
Haertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Vogt, C., Fernández, R. A., Bittrich, M., Ruiz-Heredia, Y., Da Viá, M., et al. (2021) · Blood · doi:10.1182/blood.2020010452 · Cited by 49
USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Nguyen, T. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111391118 · Cited by 53
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Molecular glues to stabilise protein–protein interactions
Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 51
Emerging strategies for prospective discovery of molecular glue degraders
Wang, B., Cao, S., & Zheng, N. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102811 · Cited by 52
Leblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 53
Emerging Roles of SKP2 in Cancer Drug Resistance
Wu, T., Gu, X., & Cui, H. (2021) · Cells · doi:10.3390/cells10051147 · Cited by 51
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49
Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., Vacca, A., & Montagnani, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092513 · Cited by 49
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Ichikawa, S., Payne, N. C., Xu, W., Chang, C., Vallavoju, N., Frome, S., Flaxman, H. A., Mazitschek, R., & Woo, C. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.003 · Cited by 51
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 52
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma
Auner, H. W., & Cenci, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13172 · Cited by 49
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
North, B. J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S. S., & Quayle, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173507 · Cited by 49
Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T. X., Robert, N., Requirand, G., Boireau, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0025-x · Cited by 50
Factors Regulating microRNA Expression and Function in Multiple Myeloma
Misiewicz-Krzemińska, I., Krzemiński, P., Corchete, L. A., Quwaider, D., Rojas, E. A., Herrero, A. B., & Gutierrez, N. C. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010009 · Cited by 51
Mechanisms of lenalidomide sensitivity and resistance
Martinez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 46
Development of CDK4/6 Inhibitors: A Five Years Update
Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 48
Ramberger, E., Sapozhnikova, V., Ng, Y. L. D., Dolnik, A., Ziehm, M., Popp, O., Sträng, E., Kull, M., Grünschläger, F., Krüger, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00784-3 · Cited by 48
Wu, J., Kumar, S., Wang, F., Wang, H., Chen, L., Arsenault, P., Mattern, M. R., & Weinstock, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00498 · Cited by 49
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 49
Yang, J., Huang, M. J., Zhou, L., He, X., Jiang, X., Zhang, Y., & Xu, G. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002246 · Cited by 51
Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 48
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
“Upon binding to CRBN, IMiDs act as molecular glues, enhancing the recruitment of a wide range of zinc-fi nger containing transcription factors and other proteins as CRBN neo -sub- strates leading to their rapid ubiquitination and degradation 12 – 14 .”
BackgroundXu, Q., Hou, Y.-X., Langlais, P. R., Erickson, P. W., Zhu, J. J., Shi, C.-X., Luo, M., Zhu, Y., Xu, Y., Mandarino, L. J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2331-0 · Cited by 48
Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity
Sebastian, S., Zhu, Y. X., Braggio, E., Shi, C.-X., Panchabhai, S. C., Wier, S. A. V., Ahmann, G. J., Chesi, M., Bergsagel, P. L., Stewart, A. K., et al. (2016) · Blood · doi:10.1182/blood-2016-09-738872 · Cited by 47
Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy
Dahl, M., Kristensen, L. S., & Grønbæk, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092475 · Cited by 50
Carbonneau, S., Sharma, S. P., Peng, L., Rajan, V., Hainzl, D., Hénault, M., Yang, C., Hale, J. A., Shulok, J. R., Tallarico, J. A., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.012 · Cited by 49
Self-citationKrönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
Quality control of protein complex composition
Padovani, C., Jevtić, P., & Rapé, M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.029 · Cited by 48
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 47
Deregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 48
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
Bolomsky, A., Ceribelli, M., Scheich, S., Rinaldi, K., Huang, D. W., Chakraborty, P., Pham, L., Wright, G. W., Hsiao, T., Morris, V. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.026 · Cited by 48
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Kagiou, C., Cisneros, J. A., Farnung, J., Liwocha, J., Offensperger, F., Dong, K. D., Yang, K., Tin, G., Horstmann, C. S., Hinterndorfer, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49739-3 · Cited by 53
Patil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 43
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Cucè, M., Cantafio, M. E. G., Siciliano, M. A., Riillo, C., Caracciolo, D., Scionti, F., Staropoli, N., Zuccalà, V., Maltese, L., Vito, A. D., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0714-9 · Cited by 47
Song, Y. Y., Park, P. M. C., Wu, L., Ray, A., Picaud, S., Li, D., Wimalasena, V. K., Du, T., Filippakopoulos, P., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0467-z · Cited by 49
Matyskiela, M. E., Zhu, J., Baughman, J. M., Clayton, T., Slade, M., Wong, H. K., Danga, K., Zheng, X., Labow, M., LeBrun, L., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00674 · Cited by 44
Self-citationPathogenesis and treatment of multiple myeloma
Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 54
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
Ma, H., Davarifar, A., & Amengual, J. E. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0432-3 · Cited by 45
Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues
Hassan, M. M., Li, Y.-D., Ma, M. W., Teng, M., Byun, W. S., Puvar, K., Lumpkin, R. J., Sandoval, B., Rutter, J. C., Jin, C. Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116904 · Cited by 47
Hemoglobin genetics: recent contributions of GWAS and gene editing
Smith, E. C., & Orkin, S. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw170 · Cited by 45
Chung, C.-I., Zhang, Q., & Shu, X. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03476 · Cited by 47
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Hao, B.-B., Li, X.-J., Jia, X.-L., Wang, Y.-X., Zhai, L.-H., Li, D.-Z., Liu, J., Zhang, D., Chen, Y.-L., Xu, Y.-H., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0367-9 · Cited by 42
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 44
Development of Photolenalidomide for Cellular Target Identification
Lin, Z., Amako, Y., Kabir, F., Flaxman, H. A., Budnik, B., & Woo, C. M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11920 · Cited by 45
Targeting oncoproteins with a positive selection assay for protein degraders
Koduri, V., Duplaquet, L., Lampson, B. L., Wang, A. C., Sabet, A. H., Ishoey, M., Paulk, J., Teng, M., Harris, I. S., Endress, J. E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6263 · Cited by 44
“In our initial proof-of-concept experiments, we used this virus to create 293FT cells expressing the IMiD target IKZF1 (1, 2, 5) fused to DCK* and compared them to cells expressing unfused DCK* or unfused IKZF1 (Fig.”
BackgroundMethodSelf-citationEladl, O. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117297 · Cited by 44
Simoes, R. D. M., Shirasaki, R., Downey-Kopyscinski, S. L., Matthews, G. M., Barwick, B. G., Gupta, V. A., Dupéré-Richer, D., Yamano, S., Hu, Y., Sheffer, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00550-x · Cited by 45
Self-citationEmerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 47
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Forster, S., Radpour, R., & Ochsenbein, A. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243997 · Cited by 45
Drug Discovery Approaches to Target E3 Ligases
Rodríguez-Gimeno, A., & Galdeano, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400656 · Cited by 45
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor-Ruiz, C., & Winter, G. E. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 41
The evolution of our understanding of macrophages and translation of findings toward the clinic
Martínez, F. O., & Gordon, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.985658 · Cited by 48
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications
Helzer, K. T., Hooper, C., Miyamoto, S., & Alarid, E. T. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0308 · Cited by 45
Shen, C., Nayak, A., Neitzel, L. R., Adams, A. A., Silver-Isenstadt, M., Sawyer, L. M., Benchabane, H., Wang, H., Bunnag, N., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25634-z · Cited by 43
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 45
High-throughput ligand diversification to discover chemical inducers of proximity
Shaum, J. B., Ordoño, M. M. I., Steen, E. A., Wenge, D. V., Cheong, H., Janowski, J., Hunkeler, M., Bilotta, E. M., Rutter, Z. J., Barta, P. A., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02137-2 · Cited by 46
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 44
PROTACs: New method to degrade transcription regulating proteins
Hu, B., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 41
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 47
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.